Table 3. Comparison of anti-EBV antibodies in ≤30 years old non-nasopharyngeal carcinoma patients with various symptoms at the PUMC Hospital, Beijing, 2013–2017.
| VCA IgG Pos no. (%) |
VCA IgM Pos no. (%) |
VCA IgA Pos no. (%) |
EA/D IgA Pos no. (%) |
EBNA1 IgG Pos no. (%) |
χ2/P-value | |
|---|---|---|---|---|---|---|
| FUO | 534(83.57) | 92(9.89) | 106(18.06) | 66(10.59) | 319(79.35) | |
| Lymphadenopathy | 119(88.15) | 32(16.41) | 18(16.98) | 11(9.65) | 38(82.61) | 9.59/0.002* |
| Elevated serum liver enzymes | 62(86.11) | 18(13.33) | 17(27.87) | 16(22.86) | 31(75.61) | 8.74/0.003** |
| Total of ≤30y non-NPC | 2261(88.49) | 331(9.38) | 475(21.52) | 250(10.82) | 1046(81.40) |
FUO: Fever of unknown origin
Non-NPC: Non- nasopharyngeal carcinoma
* Comparison of anti-VCA IgM antibodies between ≤30 year old non-NPC patients with lymphadenopathy and total of ≤30 year old non-NPC patients;
** Comparison of anti-EA/D IgA antibodies between ≤30 year old non-NPC patients with elevated serum liver enzymes and total of ≤30 year old non-NPC patients.